What is Zacks Research’s Estimate for PCRX FY2024 Earnings?

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Equities researchers at Zacks Research upped their FY2024 EPS estimates for shares of Pacira BioSciences in a research note issued on Wednesday, December 11th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $2.60 per share for the year, up from their previous forecast of $2.36. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.32 per share. Zacks Research also issued estimates for Pacira BioSciences’ Q2 2025 earnings at $0.58 EPS, FY2025 earnings at $2.30 EPS, Q1 2026 earnings at $0.61 EPS and FY2026 earnings at $2.64 EPS.

PCRX has been the topic of a number of other reports. HC Wainwright reaffirmed a “buy” rating and issued a $39.00 target price on shares of Pacira BioSciences in a report on Wednesday, December 4th. Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Pacira BioSciences in a report on Friday, November 8th. Jefferies Financial Group lifted their price objective on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. Royal Bank of Canada lifted their target price on shares of Pacira BioSciences from $15.00 to $16.00 and gave the company a “sector perform” rating in a report on Thursday, November 7th. Finally, Barclays cut their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a report on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $23.50.

Pacira BioSciences Price Performance

PCRX stock opened at $19.83 on Monday. The stock has a market cap of $915.61 million, a price-to-earnings ratio of -9.79 and a beta of 0.80. Pacira BioSciences has a fifty-two week low of $11.16 and a fifty-two week high of $35.95. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The business has a 50 day moving average price of $17.35 and a 200 day moving average price of $18.89.

Institutional Investors Weigh In On Pacira BioSciences

Hedge funds have recently modified their holdings of the stock. Innealta Capital LLC acquired a new stake in shares of Pacira BioSciences during the second quarter worth approximately $50,000. nVerses Capital LLC raised its holdings in shares of Pacira BioSciences by 800.0% during the second quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock worth $51,000 after purchasing an additional 1,600 shares during the period. Quest Partners LLC bought a new position in shares of Pacira BioSciences in the 2nd quarter worth about $113,000. Canada Pension Plan Investment Board acquired a new stake in shares of Pacira BioSciences during the 2nd quarter worth approximately $140,000. Finally, Virtus Investment Advisers Inc. acquired a new position in Pacira BioSciences during the 3rd quarter valued at approximately $98,000. 99.73% of the stock is currently owned by hedge funds and other institutional investors.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.